SOX17 and non-small cell lung carcinoma: Hulbert et al. (Hulbert et al. 2017) reported that the combination of CDO1, TAC1 and SOX17 in plasma showed a sensitivity, specificity and AUC of 86%, 78% and 77% in the diagnosis of non-small cell lung cancer with stage I and IIA from the individuals with non-cancer.